The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) Enter a Strategic Partnership for the Study of NASH
Retrieved on:
Wednesday, September 7, 2022
Beaujon Hospital, Partnership, Vascular disease, Paris Diderot University, CEO, National Institute, Imaging, SIB, Artificial intelligence, Liver, INSERM, Trial of the century, CEA, Seminal vesicles, Pathology, Artificiality, Digital pathology, Commissariat, Physics, Swiss Institute of Bioinformatics, Fatty liver disease, Diagnosis, Diabetes, Medical research, Inflammation, Type 2 diabetes, Fibrosis, GLOBE, Biostatistics, Leadership, Princeton University, NASH, University, Assistance, Data, Patient, QUID, Medical imaging, T2D, Beaujon
The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.
Key Points:
- The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.
- This dataset will enrich the data collected and enable the consortium to discover novel histological phenotypes of NASH in T2D patients.
- Its multivendor platform, FibroNest, is delivered worldwide via the cloud and used in multiple pre-clinical and clinical studies across several fibrotic conditions.
- For more information about FibroNest and PharmaNest, visit www.pharmanest.com and www.fibronest.com